Business Wire

MAVENIR

14.12.2021 09:03:17 CET | Business Wire | Press release

Share
Vodafone and Mavenir Complete First Call Over Containerised Open RAN Solution

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today that Vodafone and Mavenir have completed the first data and Voice over LTE (VoLTE) call across a containerised 4G small cell Open RAN solution in a lab environment. The completed tests are the latest steps forward to delivering an open and vendor-interoperable 4G connectivity solution for small to medium-sized office locations.

Having first started work on a containerised indoor enterprise connectivity solution in January 2021, Vodafone has completed tests for an important stage of the technology roadmap. The plug-and-play small cell equipment can ensure comprehensive mobile coverage in every corner of the office. The solution will provide 4G coverage initially, making use of radio hardware from Sercomm and software from Mavenir (Open RAN).

This demonstration of a containerised solution is a major milestone in the evolution of connectivity equipment away from physical infrastructure to a digital cloud-based environment. Containerisation provides greater flexibility for customers, but also significant benefits in terms of speed and cost of deployment.

Containerisation means that software can be seamlessly transferred between equipment, platforms, and applications. Wind River provided its Containers as a Service (CaaS) software, part of Wind River Studio.

Moving forward, Vodafone and Mavenir will focus on finalising the packaging and automation of the solution before beginning trials with selected customers.

Open RAN technology separates software from hardware, meaning more flexibility for mobile operators and customers. The approach will see many companies providing the components that make up a mobile network site, where previously one vendor would have delivered the whole solution. The technology is widely accepted as a disruptor for the telecommunications industry, and Vodafone is one of the industry leaders in supporting the development of this vendor ecosystem.

Whereas much of the focus for Open RAN has been directed towards network infrastructure deployment on mobile sites throughout the UK, the technology can be implemented in an enterprise environment to support local connectivity requirements. As an interoperable and standardised technology, Open RAN solutions can be integrated with little disruption in a “plug and play” manner, interoperable with other Open RAN compliant vendors.

Andrea Dona, Chief Network Officer, Vodafone UK, said ; “Open RAN is opening doors to simplified and intuitive connectivity solutions. For our wider network deployment strategy, Open RAN is enabling us to work with a wider pool of suppliers and to avoid vendor lock-in scenarios that might prevent us from taking advantage of the latest innovations. The same could be said for enterprise connectivity solutions.

“From the moment Open RAN is deployed in an office environment, customers are no-longer locked into a single upgrade path. Working alongside Vodafone, customers can be more flexible in how connectivity solutions are adapted and upgraded as demands evolve in the future.”

Stefano Cantarelli, Executive Vice President and Chief Marketing Officer, Mavenir, said ; “Cloud Native and Open Solutions are becoming the new reality of the mobile world, and these include Radio Access and its containerised implementation. Open vRAN is a very flexible architecture that can serve any type of segment and Mavenir is really pleased to work with Vodafone in the enterprise business and achieved another first together. It is an opportunity to show that automated and AI controlled systems will simplify life to business and industry.”

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

About Vodafone UK

Vodafone UK is a technology communications company that connects people, businesses and devices to help our customers benefit from digital innovation. Our services span mobile, fixed-line connections, home and office broadband, and the Internet of Things (IoT). www.vodafone.co.uk

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release

The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio

Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release

Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release

Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'

SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release

Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye